36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04173650 (ClinicalTrials.gov) | October 2023 | 18/11/2019 | MSC EVs in Dystrophic Epidermolysis Bullosa | A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds | Dystrophic Epidermolysis Bullosa | Drug: AGLE 102 | Aegle Therapeutics | NULL | Not yet recruiting | 6 Years | N/A | All | 10 | Phase 1/Phase 2 | NULL |